Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
carboplatin (paraplatin) (1 trial)
oregovomab (2 trials)
paclitaxel (taxol) (1 trial)
poly-iclc (1 trial)
Carcinoma, Ovarian Epithelial (Phase 1)
Ovarian Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (4 total)